Cellectis’s UCART20x22 Trial in NHL Starts Enrollment; Precision’s Azer-cel and PBCAR19B Programs Delayed; Poseida to Provide Further Clinical Updates in 2023; Cellectis, Precision, and Poseida Q4 2022 Earnings Calls Summary
Here is a brief preview of this blast: On Thursday, March 9, the following companies released their Q4 and FY 2022 earnings providing clinical updates and financial results: